Table 1
PK [patients remaining on LPV/r SGC (n = 10)] | Wk 4 | Wk 48 | GMR (95% CI) | CV% wk 4; wk 48 |
LPV AUC0–12, ng.h/ml | 102951 (85318, 130692) | 91589 (84050, 101101) | 0.89 (0.70, 1.13) | 34; 15 |
LPV Ctrough, ng/ml | 4848 (3615, 7952) | 5230 (4347, 6794) | 1.08 (0.67, 1.75) | 60; 35 |
LPV Cmax, ng/ml | 12307 (10659, 14663) | 11115 (10209, 12251) | 0.90 (0.75, 1.08) | 26; 15 |
NVP AUC0–12, ng.h/ml | 71850 (67089, 90850) | 68793 (58059, 86236) | 0.96 (0.83, 1.10) | 45; 33 |
NVP Ctrough, ng/ml | 5254 (4933, 6676) | 4932 (4032, 6527) | 0.94 (0.76, 1.16) | 45; 40 |
NVP Cmax, ng/ml | 6924 (6440, 8741) | 6830 (5846, 8385) | 0.99 (0.85, 1.15) | 46; 30 |
PK [patients switching to LPV/r tablet (n = 15)] | Wk 4 | Wk 48 | GMR (95% CI) | CV% wk 4; wk 48 |
LPV AUC0–12, ng.h/ml | 77332 (68401, 87428) | 67853 (60277, 85324) | 0.88 (0.67, 1.14) | 26; 34 |
LPV Ctrough, ng/ml | 3171 (2355, 4271) | 2164 (2013, 3688) | 0.68 (0.37, 1.24) | 62; 58 |
LPV Cmax, ng/ml | 9393 (8619, 10518) | 8706 (7618, 10846) | 0.93 (0.76, 1.12) | 20; 35 |
NVP AUC0–12, ng.h/ml | 55289 (49589, 64356) | 57231 (50758, 64528) | 1.04 (0.88, 1.21) | 26; 26 |
NVP Ctrough, ng/ml | 3984 (3842, 4947) | 4063 (3540, 4665) | 1.02 (0.86, 1.21) | 28; 29 |
NVP Cmax, ng/ml | 5447 (4918, 6251) | 5576 (5004, 6469) | 1.02 (0.88, 1.20) | 24; 25 |